Risk of Bleeding from Antithrombotic Agents (AT) in Patients with Cerebral Cavernous Malformations (CCMs). (I2-1.002)

CONCLUSIONS: There is no apparent increase in the rate of hemorrhage in CCM patients while taking AT, although the small number of patients may limit the power to detect a difference. We are expanding this study to include a larger clinical database.Study Supported by:Disclosure: Dr. Wityk has nothing to disclose.

http://www.neurology.org/cgi/content/short/82/10_Supplement/I2-1.002?rss=1

Source: Neurology - April 9, 2014 Category: Neurology Authors: Wityk, R. Tags: New Antithrombotic Agents for Stroke Prevention Poster Presentations Source Type: research